Orphanin FQ acts as an anxiolytic to attenuate behavioral responses to stress
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
Orphanin FQ (OFQ, Nociceptin) is a recently discovered 17-amino acid neuropeptide that is structurally related to the opioid peptides but does not bind opioid receptors. OFQ has been proposed to act as an anti-opioid peptide, but its widespread sites of action in the brain suggest that it may have more general functions. Here we show that OFQ plays an important role in higher brain functions because it can act as an anxiolytic to attenuate the behavioral inhibition of animals acutely exposed to stressful/anxiogenic environmental conditions. OFQ anxiolytic-like effects were consistent across several behavioral paradigms generating different types of anxiety states in animals (light-dark preference, elevated plus-maze, exploratory behavior of an unfamiliar environment, pharmacological anxiogenesis, operant conflict) and were observed at low nonsedating doses (0.1–3 nmol, intracerebroventricular). Like conventional anxiolytics, OFQ interfered with regular sensorimotor function at high doses (>3 nmol). Our results show that an important role of OFQ is to act as an endogenous regulator of acute anxiety responses. OFQ, probably in concert with other major neuropeptides, exerts a modulatory role on the central integration of stressful stimuli and, thereby, may modulate anxiety states generated by acute stress.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Validation of open:closed arm entries in an elevated plus-maze as a measure of anxiety in the rat
Pellow, S., Chopin, P., File, S. E., & Briley, M. (1985) · Journal of Neuroscience Methods · doi:10.1016/0165-0270(85)90031-7 · Cited by 5,822
Neurocircuitry of stress: central control of the hypothalamo–pituitary–adrenocortical axis
Herman, J. P., & Cullinan, W. E. (1997) · Trends in Neurosciences · doi:10.1016/s0166-2236(96)10069-2 · Cited by 2,270
Isolation and structure of the endogenous agonist of opioid receptor-like ORL1 receptor
Meunier, J.-C., Mollereau, C., Toll, L., Suaudeau, C., Moisand, C., Alvinerie, P., Butour, J.-L., Guillemot, J.-C., Ferrara, P., Monsarrat, B., et al. (1995) · Nature · doi:10.1038/377532a0 · Cited by 1,912
Orphanin FQ: A Neuropeptide That Activates an Opioidlike G Protein-Coupled Receptor
Reinscheid, R. K., Nothacker, H.-P., Bourson, A., Ardati, A., Henningsen, R. A., Bunzow, J. R., Grandy, D. K., Langen, H., Monsma, F. J., & Civelli, O. (1995) · Science · doi:10.1126/science.270.5237.792 · Cited by 1,821
Self-citationVaughan, J., Donaldson, C., Bittencourt, J., Perrin, M. H., Lewis, K., Sutton, S., Chan, R., Turnbull, A. V., Lovejoy, D., Rivier, C., et al. (1995) · Nature · doi:10.1038/378287a0 · Cited by 1,479
Preliminary report of a simple animal behavior model for the anxiolytic effects of benzodiazepines
Crawley, J., & Goodwin, F. K. (1980) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(80)90067-2 · Cited by 1,425
ORL1, a novel member of the opioid receptor family: Cloning, functional expression and localization
Mollereau, C., Parmentier, M., Mailleux, P., Butour, J.-L., Moisand, C., Chalon, P., Caput, D., Vassart, G., & Meunier, J.-C. (1994) · FEBS Letters · doi:10.1016/0014-5793(94)80235-1 · Cited by 1,077
Ethologically-based animal models of anxiety disorders
Lister, R. G. (1990) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(90)90021-s · Cited by 845
Geller, I., & Seifter, J. (1960) · Psychopharmacologia · doi:10.1007/bf00429273 · Cited by 780
Bunzow, J. R., Saez, C., Mortrud, M., Bouvier, C., Williams, J. T., Low, M., & Grandy, D. K. (1994) · FEBS Letters · doi:10.1016/0014-5793(94)00561-3 · Cited by 607
Cited by
Drug Addiction, Dysregulation of Reward, and Allostasis
Koob, G. (2001) · Neuropsychopharmacology · doi:10.1016/s0893-133x(00)00195-0 · Cited by 2,953
“1996), although more recent evidence suggests that orphanin FQ produces more anxiolytic-like effects (Jenck et al. 1997).”
BackgroundResultThe neurobiology and control of anxious states
Millan, M. J. (2003) · Progress in Neurobiology · doi:10.1016/s0301-0082(03)00087-x · Cited by 965
Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease
Bastide, M. F., Meissner, W. G., Picconi, B., Fasano, S., Fernagut, P.-O., Feyder, M., Francardo, V., Alcacer, C., Ding, Y., Brambilla, R., et al. (2015) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2015.07.002 · Cited by 475
The Molecular and Behavioral Pharmacology of the Orphanin FQ/Nociceptin Peptide and Receptor Family
Mogil, J. S., & Pasternak, G. W. (2001) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01502-3 · Cited by 441
Pharmacology of nociceptin and its receptor: a novel therapeutic target
Calo', G., Guerrini, R., Rizzi, A., Salvadori, S., & Regoli, D. (2000) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0703219 · Cited by 437
Neal, C. R., Mansour, A., Reinscheid, R., Nothacker, H.-P., Civelli, O., & Watson, S. J. (1999) · The Journal of Comparative Neurology · doi:10.1002/(sici)1096-9861(19990419)406:4<503::aid-cne7>3.0.co;2-p · Cited by 397
Self-citationPharmacological treatment of alcohol dependence: Target symptoms and target mechanisms
HEILIG, M., & EGLI, M. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2006.02.001 · Cited by 377
Review of recent advances in analytical techniques for the determination of neurotransmitters
Perry, M., Li, Q., & Kennedy, R. T. (2009) · Analytica Chimica Acta · doi:10.1016/j.aca.2009.08.038 · Cited by 367
The nociceptin/orphanin FQ receptor: a target with broad therapeutic potential
Lambert, D. G. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2572 · Cited by 357
Neal, C. R., Mansour, A., Reinscheid, R., Nothacker, H.-P., Civelli, O., Akil, H., & Watson, S. J. (1999) · The Journal of Comparative Neurology · doi:10.1002/(sici)1096-9861(19991004)412:4<563::aid-cne2>3.0.co;2-z · Cited by 356
Self-citationToll, L., Bruchas, M. R., Calo', G., Cox, B. M., & Zaveri, N. T. (2016) · Pharmacological Reviews · doi:10.1124/pr.114.009209 · Cited by 297
The Mouse Defense Test Battery: pharmacological and behavioral assays for anxiety and panic
Blanchard, D. C., Griebel, G., & Blanchard, R. J. (2003) · European Journal of Pharmacology · doi:10.1016/s0014-2999(03)01276-7 · Cited by 295
“The neuropeptide was found to exert anxiolyticlike action in the elevated plus-maze and light/dark tests (Jenck et al., 1997) and prevented stress-induced anorexia (Ciccocioppo et al.”
BackgroundCastro, D. C., & Bruchas, M. R. (2019) · Neuron · doi:10.1016/j.neuron.2019.03.003 · Cited by 290
A synthetic agonist at the orphanin FQ/nociceptin receptor ORL1: Anxiolytic profile in the rat
Jenck, F., Wichmann, J., Dautzenberg, F. M., Moreau, J.-L., Ouagazzal, A. M., Martin, J. R., Lundstrom, K., Cesura, A. M., Poli, S. M., Roever, S., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.090514397 · Cited by 275
Self-citationKöster, A., Montkowski, A., Schulz, S., Stübe, E.-M., Knaudt, K., Jenck, F., Moreau, J.-L., Nothacker, H.-P., Civelli, O., & Reinscheid, R. K. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.18.10444 · Cited by 247
Self-citationKawamoto, H., Ozaki, S., Itoh, Y., Miyaji, M., Arai, S., Nakashima, H., Kato, T., Ohta, H., & Iwasawa, Y. (1999) · Journal of Medicinal Chemistry · doi:10.1021/jm990517p · Cited by 204
Descalzi, G., Mitsi, V., Purushothaman, I., Gaspari, S., Avrampou, K., Loh, Y.-H. E., Shen, L., & Zachariou, V. (2017) · Science Signaling · doi:10.1126/scisignal.aaj1549 · Cited by 188
Witkin, J. M., Statnick, M. A., Rorick-Kehn, L. M., Pintar, J. E., Ansonoff, M., Chen, Y., Tucker, R. C., & Ciccocioppo, R. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.10.011 · Cited by 194
“both leads to marked anxiolytic-like effects in rodents (Gavioli et al., 2006;Varty et al., 2005; Jenck et al., 1997; Goeldner et al., 2012).”
BackgroundCiccocioppo, R., Fedeli, A., Economidou, D., Policani, F., Weiss, F., & Massi, M. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-28-09445.2003 · Cited by 137
The Role of the Central Amygdala in Alcohol Dependence
Roberto, M., Kirson, D., & Khom, S. (2021) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a039339 · Cited by 112
“Earlier studies showed that nociceptin and other NOP agonists have an anxiolytic-like profile in animal studies (Jenck et al. 1997; Jenck et al. 2000), and nociceptin knockout mice show increased anxiety-like behavior (Koster et al. 1999) and are more sensitive to social stress (Ouagazzal et al.…”
BackgroundCiccocioppo, R., Economidou, D., Fedeli, A., & Massi, M. (2003) · Physiology & Behavior · doi:10.1016/s0031-9384(03)00112-4 · Cited by 74
Modulation of cellular activity and synaptic transmission in the ventral tegmental area
Mathon, D. S., Kamal, A., Smidt, M. P., & Ramakers, G. M. J. (2003) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2003.08.097 · Cited by 41
Walker, J. (2002) · Neuropsychopharmacology · doi:10.1016/s0893-133x(02)00292-0 · Cited by 13
“Because the frontal cortex is involved in stress and nociceptin has been implicated as an endogenous anxiolytic, we sought to determine whether the change in nociceptin peptide levels might be a response to a stressful component of conditioned withdrawal (Horger and Roth 1996; Jenck et al. 1997).”
Background
Metadata
- Authors
- Jenck, F., Moreau, J.-L., Martin, J. R., Kilpatrick, G. J., Reinscheid, R. K., Monsma, F. J., Nothacker, H.-P., & Civelli, O.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 1997-12-23
- Volume
- 94
- Issue
- 26
- Pages
- 14854-14858
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2078867001
- Cited by
- 347
- References
- 34
- FWCI
- 5.32
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.